Accordingly, specific recommendations for both CHEK2 and PALB2 testing and carrier monitoring have been included in the National Comprehensive Cancer Network (NCCN) guidelines for breast and/or ovarian cancer susceptibility evaluation; moreover, an association with limited strength of evidence has also been reported between CHEK2 pathogenic variants and colon cancer risk and PALB2 pathogenic variants and pancreatic cancer risk [12]. Here, PALB2 is linked to familial pancreatic carcinoma.